<DOC>
	<DOCNO>NCT01213485</DOCNO>
	<brief_summary>This observational study evaluate course treatment , efficacy anemia safety Mircera ( methoxy polyethylene glycol-epoetin beta ) patient chronic kidney disease dialysis . Eligible patient either haemodialysis peritoneal dialysis treatment-naïve prior therapy erythropoiesis stimulate agent ( ESA ) . Data collect patient 12 month .</brief_summary>
	<brief_title>An Observational Study Mircera ( Methoxy Polyethylene Glycol-Epoetin Beta ) Patients With Chronic Kidney Disease Dialysis ( HORTENSIA )</brief_title>
	<detailed_description />
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<criteria>Adult patient , &gt; /= 18 year age Chronic kidney disease , dialysis &gt; 3 month Treatmentnaïve previous treatment ESA Initiation treatment Mircera renal insufficiency associate anemia decision treat physician Participation clinical trial Anemia due associate malignant pathology</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>